A Study to Evaluate Efficacy and Safety of HS-10374 for Moderate to Severe Plaque Psoriasis

PHASE2RecruitingINTERVENTIONAL

Enrollment

120

Participants

Timeline

Start Date

September 28, 2023

Primary Completion Date

July 31, 2024

Study Completion Date

August 31, 2024

Conditions

Psoriasis

Interventions

DRUG

HS-10374 tablets 1mg

Administered orally QD for 12 weeks

DRUG

HS-10374 tablets 5mg

Administered orally QD for 12 weeks

DRUG

HS-10374-matched placebo tablets

Administered orally QD for 12 weeks

Trial Locations (1)

RECRUITING

Huashan Hospital of Fudan University, Shanghai

All Listed Sponsors

lead

Hansoh BioMedical R&D Company

INDUSTRY